

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10596930	
	Filing Date		2006-06-29	
	First Named Inventor	Susan Ashwell		
	Art Unit	1761		
	Examiner Name	Keith D. Hendricks		
	Attorney Docket Number	101367-1P US		

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	7423061	B2	2008-09-09	AstraZeneca AB			
	2	6187799	B1	2001-02-13	Onyx Pharmaceuticals and Bayer Corporation			
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2001098290	WO	A2	2001-12-27	Pharmacia & Upjohn S.P. A.		<input type="checkbox"/>
	2	2004063185	WO	A1	2004-07-29	AstraZeneca AB AstraZeneca UK Limited		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10596930
Filing Date		2006-06-29
First Named Inventor	Susan Ashwell	
Art Unit	1761	
Examiner Name	Keith D. Hendricks	
Attorney Docket Number	101367-1P US	

3	2003029241	WO	A1	2003-04-10	SmithKline Beecham Corporation		<input type="checkbox"/>
4	2003028731	WO	A1	2003-04-10	SmithKline Beecham Corporation		<input type="checkbox"/>
5	9852558	WO	A1	1998-11-26	Bayer Corporation		<input type="checkbox"/>
6	2005033102	WO	A2	2005-04-14	Amphora Discovery Corporation		<input type="checkbox"/>
7	2006062982	WO	A2	2006-06-15	Locus Pharmaceuticals Inc		<input type="checkbox"/>
8	2006062984	WO	A2	2006-06-15	Locus Pharmaceuticals Inc		<input type="checkbox"/>
9	2001058890	WO	A1	2001-08-16	AstraZeneca AB		<input type="checkbox"/>
10	2002030353	WO	A2	2002-04-18	SmithKline Beecham Corporation		<input type="checkbox"/>
11	2003029242	WO	A1	2003-04-10	SmithKline Beecham Corporation		<input type="checkbox"/>
12	2003104218	WO	A1	2003-12-18	SmithKline Beecham Corporation		<input type="checkbox"/>
13	2004053087	WO	A2	2004-06-24	SmithKline Beecham Corporation		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10596930
Filing Date	2006-06-29
First Named Inventor	Susan Ashwell
Art Unit	1761
Examiner Name	Keith D. Hendricks
Attorney Docket Number	101367-1P US

14	2005105777	WO	A1	2005-11-10	Pharmacia & Upjohn Company LLC	<input type="checkbox"/>
15	02070494	WO	A1	2002-09-12	ICOS Corporation	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
Not Provided	1	BAXTER et al. Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK -2 inhibitors. Bioorganic & Medicinal Chemistry Letters (2004), 14(11), 2817-2822.	<input type="checkbox"/>
	2	AstraZeneca PLC, Novel thiophenecarboxamide IKK -2 inhibitors. Expert Opinion on Therapeutic Patents (2005), 15(3), 343-347.	<input type="checkbox"/>
	3	JANETKA, James, "Discovery of AZD7762 and a Novel Class of Thiophene Carboxamide Urea Checkpoint Kinase Inhibitors", presentation at Protein Kinase Targets, Drug Discovery and Design, Cambridge Health Institute, Boston, MA, USA; 7 September 2008.	<input type="checkbox"/>
	4	ASHWELL, Susan, "Pre-clinical Profile of AZD7762, a Novel, Potent and Selective Inhibitor of Checkpoint Kinases", presentation at AACR, Los Angeles, CA, USA; 14 April 2007.	<input type="checkbox"/>
	5	ASHWELL, Susan, presentation at AACR-NCI-EORTC, San Francisco, CA, USA; 22 October 2007.	<input type="checkbox"/>
	6	JANETKA, James, presentation at AACR-NCI-EORTC, San Francisco, CA, USA; 22 October 2007.	<input type="checkbox"/>
	7	ASHWELL, Susan, et al., "Keeping Checkpoint Kinases in Line: New selective inhibitors in clinical trials" Expert Opinion Investigative Drugs (2008) 17(9):1331-1340.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10596930
Filing Date	2006-06-29
First Named Inventor	Susan Ashwell
Art Unit	1761
Examiner Name	Keith D. Hendricks
Attorney Docket Number	101367-1P US

8	JANETKA, James W et al., "Inhibitors of checkpoint Kinases: From discovery to the clinic" Current Opinion in Drug Discovery and Development 2007; 10(4):473-486.	<input type="checkbox"/>
9	ASHWELL, Susan et al. "DNA Damage Detection and Repair Pathways-Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy. Clinical Cancer Research 2008 14(13) 4032-4037.	<input type="checkbox"/>
10	JANETKA, James W et al., "Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 18 (2008) 4242-4248.	<input type="checkbox"/>
11	ZABLUDOFF, Sonya et al., "AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. September 2008 ;7(9) : 2955-2966	<input type="checkbox"/>
12	Office Action from US Application No.: 10/568,380 (now US Patent No.: 7,423,061). Mail Date 9/10/2007.	<input type="checkbox"/>
13	ROBBA M et al., "Synthese d 'intermediaires de la thiazolo (4,5-d) pyridazine. II. Amides et hydrazides d'acides thiazole-carboxyliques" Bulletin de la Societe Chimique de France, Societe Francasie de Chimie Paris, FR, right col, 2nd, 3rd cpd. page 2155. no. 6,1969, pages 2152-2157.	<input type="checkbox"/>
14	CHILDRESS et al., "Thiazolopyrimidines" 2-Methylthiazole-4,5-dicarboxamide and 2-Phenylthiazole-4,5-dicarboxamde page 3863. J. AM. CHEM. SOC.,vol. 73, no. 26, 1951, pages 3862-3864,	<input type="checkbox"/>
15	CHAUVIN et al. "Synthesis of heterocyclic compounds from cyano- and dicyanoselephenes "Comptes Rendus Des Seances de Dessciences, Serie C: Sciences Chimiques, vol. 274, no. 14, 1972, pages 1347-1349,	<input type="checkbox"/>
16	ASHWELL S, et al., Unpublished U.S. Patent Application No.: 12/206,317.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Samira Jean-louis/	Date Considered	/Samira Jean-louis/
--------------------	---------------------	-----------------	---------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10596930
Filing Date	2006-06-29
First Named Inventor	Susan Ashwell
Art Unit	1761
Examiner Name	Keith D. Hendricks
Attorney Docket Number	101367-1P US

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.